Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 32, 2010, Pages 14158-14163

  Wu, Xinle ^a   Ge, Hongfei ^a   Lemon, Bryan ^a   Vonderfecht, Steven ^a   Baribault, Helene ^a   Weiszmann, Jennifer ^a   Gupte, Jamila ^a   Gardner, Jonitha ^a   Lindberg, Richard ^a   Wang, Zhulun ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

Author keywords

Diabetes; FGF21; FGFR4; Hepatocellular carcinoma; Hepatocyte proliferation

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLUCOSE; HEPARIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15, MOUSE; HYBRID PROTEIN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CARCINOGENICITY; CELL PROLIFERATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN SENSITIVITY; LIVER CELL; MITOGENESIS; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; ANIMAL; CYTOLOGY; DIABETES MELLITUS; GENETIC VARIABILITY; INSULIN RESISTANCE; OBESITY; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS; FIBROBLAST GROWTH FACTORS; GENETIC VARIATION; HEPATOCYTES; INSULIN RESISTANCE; MICE; OBESITY; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS;

MUS;

EID: 77956293010     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009427107     Document Type: Article

References (23)

1. Goetz R, et al. (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27:3417-3428.
2. Asada M, et al. (2008) Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim Biophys Acta 1780:1432-1440.
3. Wu X, Li Y (2009) Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis. Aging (Albany NY) 1:1023-1027.
4. Xu J, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-259.
5. Coskun T, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018-6027.
6. Fu L, et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145:2594-2603.
7. Tomlinson E, et al. (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741-1747.
8. Inagaki T, et al. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425.
9. Xu J, et al. (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin resistant mouse models - Association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297:1105-1114.
10. Wu X, et al. (2009) Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci USA 106:14379-14384.
11. Li X, et al. (2009) Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Lett 583:3230-3234.
12. Nicholes K, et al. (2002) A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160:2295-2307.
13. Wu X, et al. (2010) FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 285:5165-5170.
14. Ornitz DM, Itoh N (2001) Fibroblast growth factors. Genome Biol 2:reviews3005.
15. Zhang X, et al. (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281:15694-15700. (Pubitemid 43848456)
16. Mohammadi M, Olsen SK, Ibrahimi OA (2005) Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16:107-137.
17. Kurosu H, et al. (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120-6123.
18. Wu X, et al. (2007) Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem282:29069-29072.
19. Kurosu H, et al. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687-26695.
20. Inagaki T, et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225.
21. Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637-1647. (Pubitemid 46870300)
22. Schlessinger J, et al. (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6:743-750.
23. Wu X, et al. (2008) C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem 283:33304-33309.